Close

Teva Pharma's (TEVA) CINQAIR Receives FDA Approval as Severe Asthma Treatment

March 23, 2016 10:57 AM EDT Send to a Friend
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced that the U.S. Food and Drug Administration (FDA) has approved CINQAIR (reslizumab) Injection ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login